Another SGLT2 inhibitor approved for type 2 diabetes


eMediNexus    22 December 2017

Ertugliflozin, a SGLT2 inhibitor has been approved to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It is to be administered orally in once-daily doses. Two dose strengths will be available: 5-mg and 15-mg tablets.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.